Measuring Attractiveness for Abuse of Prescription Opioids

被引:42
作者
Butler, Stephen F. [1 ]
Fernandez, Kathrine C. [1 ]
Chang, Alan [1 ]
Benoit, Christine [1 ]
Morey, Leslie C. [2 ]
Black, Ryan [1 ]
Katz, Nathaniel [3 ]
机构
[1] Inflexxion Inc, Newton, MA 02464 USA
[2] Texas A&M Univ, College Stn, TX USA
[3] Analges Res, Needham, MA USA
关键词
Prescription Opioids; Attractiveness; Abuse; ORAL OXYCODONE; PSYCHOMOTOR; MORPHINE;
D O I
10.1111/j.1526-4637.2009.00736.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objective. Prescription opioids are the second most misused/abused drug in the United States behind only marijuana. Recreational prescription opioid users appear to prefer some products over others; however, the extent to which attributes of any particular formulation account for such preferences has yet to be determined. The Opioid Attractiveness Technology Scaling was developed to identify the particular features of a prescription opioid that are relevant to its attractiveness for recreational use, and to use these features to model attractiveness for recreational use of particular prescription opioid formulations. Design. Four hundred and ninety-one self-reported recreational prescription opioid users identified 43 product features as being relevant to determining whether a product is "attractive" or "unattractive" for recreational use. Average ratings were used to determine appropriate weights to be applied to the features. A factor analysis yielded 10, highly differentiated factors. Five hundred and sixty-four prescription opioid abusers were then asked to rate the extent to which the 43 features identified in Study 1 were relevant to specific prescription opioid products they had used. Results. Respondents provided an overall preference rating of these products and a model was created. A random intercept model yielded a significant pseudo R-2 of 0.14 (chi-square = 310.02, degrees of freedom [df] = 10, P < 0.001). The model fit least well, albeit significantly, for abusers who preferred to swallow the drug (pseudo R-2 = 0.06; chi-square = 55.52, df = 10, P < 0.001) and best for those who preferred to inject (pseudo R-2 = 0.37; chi-square = 199.34, df = 10, P < 0.001). Conclusions. The relevance of the model is discussed along with possible modifications that might allow prediction of "attractiveness" of "abuse deterrent" formulations that have not yet been marketed.
引用
收藏
页码:67 / 80
页数:14
相关论文
共 26 条
  • [1] [Anonymous], 1999, MULTILEVEL ANAL
  • [2] Bickel R., 2007, MULTILEVEL ANAL APPL
  • [3] BROWNSTEIN JS, 2007, BREAKING NEWS FUELIN
  • [4] Butler SF, 2001, PSYCHOL ADDICT BEHAV, V15, P4
  • [5] Development and validation of an Opioid Attractiveness Scale: A novel measure of the attractiveness of opioid products to potential abusers
    Butler S.F.
    Benoit C.
    Budman S.H.
    Fernandez K.C.
    McCormick C.
    Venuti S.W.
    Katz N.
    [J]. Harm Reduction Journal, 3 (1)
  • [6] Cicchetti VD., 1994, Psychological Assessment, V6, P284, DOI DOI 10.1037/1040-3590.6.4.284
  • [7] Can drug design inhibit abuse?
    Coleman, JJ
    Bensinger, PB
    Gold, MS
    Smith, DE
    Bianchi, RP
    DuPont, RL
    [J]. JOURNAL OF PSYCHOACTIVE DRUGS, 2005, 37 (04) : 343 - 362
  • [8] Abuse of prescription drugs and the risk of addiction
    Compton, Wilson A.
    Volkow, Nora D.
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2006, 83 : S4 - S7
  • [9] Association between non-medical and prescriptive usage of opioids
    Dasgupta, N
    Kramer, ED
    Zalman, MA
    Carino, S
    Smith, MY
    Haddox, JD
    Wright, C
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2006, 82 (02) : 135 - 142
  • [10] A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002
    Gilson, AM
    Ryan, KM
    Joranson, DE
    Dahl, JL
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2004, 28 (02) : 176 - 188